Here Are Wednesday's Best Wall Street Analyst Research Calls: Block, Charles River Laboratories, Cognizant Technology, Constellation Energy, Credicorp, First Solar, GE Vernova, Huntsman, Macerich, and More

Futures are trading mixed as we hit the midweek point, as the Space Exploration Technologies (NASDAQ: SPCX) or SpaceX IPO rush is starting to fade somewhat.

24/7 Wall Street • Jun 17, 2026

This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga • Jun 17, 2026

Why ResMed (RMD) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Jun 16, 2026

ResMed: GLP-1 Threats Are Overstated

My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Other business threats come from PHG's reentrance and Apnimed's drug commercialization. While not to be overlooked, I still see RMD retaining its market dominance. The stock currently trades as if revenues are already declining and margins are contracting. But the opposite is true. Margins far exceed peers, and the top line grows at double digits.

Seeking Alpha • Jun 11, 2026

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.

Zacks Investment Research • Jun 9, 2026

Top 50 High-Quality Dividend Growth Stocks For June 2026

I track a curated universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and forward return potential. Year-to-date, the universe lags SPY and SCHD, but select names like LRCX (+343%) and KLAC (+208%) have dramatically outperformed since inception. Currently, 40 stocks offer forward return estimates of at least 10%, with 24 appearing potentially undervalued by my free cash flow model.

Seeking Alpha • Jun 8, 2026

Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million

Angelini Ventures marks its first portfolio exit as ResMed acquires Noctrix Health, validating its strategy of backing breakthrough healthcare innovation.

GlobeNewsWire • Jun 3, 2026

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript

Seeking Alpha • Jun 3, 2026

Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio

Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).

GlobeNewsWire • Jun 1, 2026

ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • May 26, 2026